Pacific View Asset Management’s Kyntra Bio KYNB Stock Holding History

Pacific View Asset Management’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-380	Closed	-$429K	–	16
2019 Q2	$429K	Buy	380 +47	+14%	+$51.4K	0.47%	45
2019 Q1	$453K	Buy	333 +122	+58%	+$165K	0.47%	40
2018 Q4	$243K	Buy	211 +54	+34%	+$60.7K	0.29%	52
2018 Q3	$239K	Sell	157 -4	-2%	-$6.16K	0.19%	84
2018 Q2	$254K	Buy	+161	New	+$210K	0.2%	92
2018 Q1	–	Sell	-278	Closed	-$328K	–	116
2017 Q4	$328K	Buy	+278	New	+$349K	0.22%	106

Other funds holding KYNB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Pacific View Asset Management's KYNB Position: Q3 2019 in Review

Pacific View Asset Management sold out of Kyntra Bio (KYNB) in Q3 2019, closing a stake of 380 shares — an estimated $429K sold.

Pacific View Asset Management first reported a position in KYNB in Q4 2017 and held it in 6 quarters. The position peaked at $453K in Q1 2019. 210 funds tracked by Wall St. Rank hold KYNB as of Q3 2019.

Pacific View Asset Management reported no remaining Kyntra Bio position as of Q3 2019 after selling out during the quarter.
Pacific View Asset Management sold 380 Kyntra Bio shares in Q3 2019, an estimated $429K.
Pacific View Asset Management first reported a position in Kyntra Bio in Q4 2017 and held it in 6 quarters.
Pacific View Asset Management's Kyntra Bio position peaked at $453K in Q1 2019.
210 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2019.

Based on Pacific View Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.